par Vertommen, E.;Van West, Dirk;Verschueren, Laura 
;Staelens, Anneleen Simone A.;Neves Ramos, D.
Référence Tijdschrift voor geneeskunde, 70, 18, page (1040-1046)
Publication Publié, 2014-09
;Staelens, Anneleen Simone A.;Neves Ramos, D.Référence Tijdschrift voor geneeskunde, 70, 18, page (1040-1046)
Publication Publié, 2014-09
Article révisé par les pairs
| Résumé : | This study reports the follow-up of 66 minors (12-17 years old) exposed to risperidone, regardless of their diagnosis. The rationale of this investigation was that the stringent in- and exclusion criteria of most current publications include only 5% of the patients of this age group. Thus, generalizing those findings remains highly questionable. Moreover, most studies are short term (≤ 12 weeks) and thus lack predictive power in the long term. 66 patients were selected out of the followup database based on the next criteria: exposure to risperidone, no concomitant use of other antipsychotics, and consultation at least once for follow-up. Diagnosis, off-label use or the use of other psychotropics were no exclusion criteria. The biometric data, the lipids, and the glucose metabolism were monitored according to the metabolic protocol. No cases of increased glycemia or diabetes mellitus were observed. Still, a significant increase in weight, abdominal circumference, diastolic blood pressure and the prevalence of lipid disorders was noticed. Regardless of the absence of the direct effects on glycemia, one should use risperidone cautiously and keep monitoring for diabetes mellitus as indirect factors, like weight gain or an increase in abdominal circumference, might contribute to the metabolic side-effects. |
